Literature DB >> 22552153

Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation.

Zhong-Bo Han1, Lin Zhong, Mu-Jian Teng, Jun-Wei Fan, Hua-Mei Tang, Jun-Yi Wu, Hong-Yuan Chen, Zhao-Wen Wang, Guo-Qiang Qiu, Zhi-Hai Peng.   

Abstract

Tumor recurrence-related microRNAs (miRNAs) in hepatocellular carcinoma (HCC) following orthotopic liver transplantation (OLT) are not clear yet. This study was designed to determine whether altered miRNA expression is associated with HCC recurrence and prognosis following OLT. 18 miRNAs, including 6 up-regulated and 12 down-regulated miRNAs were identified by microarray in primary HCC samples of patients who had developed HCC recurrence (n = 5) compared to those with non-recurrence (n = 5) following OLT by using p < 0.05 as cutoff value. The six most significantly altered miRNAs (fold change ≥ 2: miR-19a, miR-886-5p, miR-126, miR-223, miR-24 and miR-147) were further confirmed by qRT-PCR in the remaining 105 HCC samples. In receiver-operating characteristic curve analysis, this six miRNAs were of high sensitivity and specificity in predicting HCC recurrence. Using Cox regression and risk score analysis, we built a six-miRNA signature based on their qRT-PCR readings for the prediction of outcome of HCC following OLT. Kaplan-Meier and Cox proportional regression revealed this six-miRNA signature was a significant independent predictor of overall survival (log-rank p = 0.020) and recurrence-free survival (log-rank p < 0.001). Finally, the data were further reconfirmed in an independent cohort of 50 patients from another transplant center. In addition, bioinformatics Gene Ontology and pathway analysis were also performed to better understand the critical roles of these miRNAs in HCC recurrence. Our study, in addition to suggesting a different miRNA expression pattern between HCC samples of patients with recurrence and those with non-recurrence, proposes that this six-miRNA signature may serve as biomarker for prognosis of HCC patients following OLT.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552153      PMCID: PMC5528352          DOI: 10.1016/j.molonc.2012.04.001

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  37 in total

1.  Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma.

Authors:  Jian Zhou; Lei Yu; Xue Gao; Jie Hu; Jiping Wang; Zhi Dai; Jie-Fei Wang; Zhiyong Zhang; Shaohua Lu; Xiaowu Huang; Zheng Wang; Shuangjian Qiu; Xiaoying Wang; Guohuan Yang; Huichuan Sun; Zhaoyou Tang; Ying Wu; Hongguang Zhu; Jia Fan
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

Review 2.  Transplantation for liver and biliary cancer.

Authors:  R W Strong
Journal:  Semin Surg Oncol       Date:  2000 Sep-Oct

3.  MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells.

Authors:  Jing-Hua Li; Xue Xiao; Yao-Nan Zhang; Ya-Mei Wang; Li-Min Feng; Yu-Mei Wu; Yu-Xiang Zhang
Journal:  Gynecol Oncol       Date:  2010-10-13       Impact factor: 5.482

4.  Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning.

Authors:  Qing-Hai Ye; Lun-Xiu Qin; Marshonna Forgues; Ping He; Jin Woo Kim; Amy C Peng; Richard Simon; Yan Li; Ana I Robles; Yidong Chen; Zeng-Chen Ma; Zhi-Quan Wu; Sheng-Long Ye; Yin-Kun Liu; Zhao-You Tang; Xin Wei Wang
Journal:  Nat Med       Date:  2003-03-17       Impact factor: 53.440

5.  MicroRNA gene expression deregulation in human breast cancer.

Authors:  Marilena V Iorio; Manuela Ferracin; Chang-Gong Liu; Angelo Veronese; Riccardo Spizzo; Silvia Sabbioni; Eros Magri; Massimo Pedriali; Muller Fabbri; Manuela Campiglio; Sylvie Ménard; Juan P Palazzo; Anne Rosenberg; Piero Musiani; Stefano Volinia; Italo Nenci; George A Calin; Patrizia Querzoli; Massimo Negrini; Carlo M Croce
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

6.  Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.

Authors:  Hung-Wei Pan; Yueh-Hsing Ou; Shian-Yang Peng; Shu-Hsian Liu; Po-Lin Lai; Po-Hwaung Lee; Jin-Chuan Sheu; Chi-Ling Chen; Hey-Chi Hsu
Journal:  Cancer       Date:  2003-07-01       Impact factor: 6.860

7.  Survival prediction of gastric cancer by a seven-microRNA signature.

Authors:  Xiaohua Li; Ying Zhang; Yafei Zhang; Jie Ding; Kaichun Wu; Daiming Fan
Journal:  Gut       Date:  2009-11-30       Impact factor: 23.059

Review 8.  Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.

Authors:  Michael A Zimmerman; R Mark Ghobrial; Myron J Tong; Jonathan R Hiatt; Andrew M Cameron; Johnny Hong; Ronald W Busuttil
Journal:  Arch Surg       Date:  2008-02

9.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

10.  miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements.

Authors:  Ashish Lal; Francisco Navarro; Christopher A Maher; Laura E Maliszewski; Nan Yan; Elizabeth O'Day; Dipanjan Chowdhury; Derek M Dykxhoorn; Perry Tsai; Oliver Hofmann; Kevin G Becker; Myriam Gorospe; Winston Hide; Judy Lieberman
Journal:  Mol Cell       Date:  2009-09-11       Impact factor: 17.970

View more
  60 in total

1.  Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma.

Authors:  Zehra Oksuz; Mehmet Sami Serin; Engin Kaplan; Aylin Dogen; Seda Tezcan; Gonul Aslan; Gurol Emekdas; Orhan Sezgin; Engin Altintas; Eyup Naci Tiftik
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

2.  Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Lin Zhong; Mu-Jian Teng; Jun-Wei Fan; Hua-Mei Tang; Jun-Yi Wu; Hong-Yuan Chen; Zhao-Wen Wang; Guo-Qiang Qiu; Zhi-Hai Peng
Journal:  Mol Oncol       Date:  2012-04-17       Impact factor: 6.603

3.  MicroRNA-147 suppresses human hepatocellular carcinoma proliferation migration and chemosensitivity by inhibiting HOXC6.

Authors:  Cheng-Jun Sui; Feng Xu; Wei-Feng Shen; Bing-Hua Dai; Jiong-Jiong Lu; Min-Feng Zhang; Jia-Mei Yang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

4.  MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.

Authors:  Adriana Sondermann; Flavia Maziero Andreghetto; Ana Carolina Bernardini Moulatlet; Elivane da Silva Victor; Marilia Germanos de Castro; Fábio Daumas Nunes; Lenine Garcia Brandão; Patricia Severino
Journal:  Clin Exp Metastasis       Date:  2015-05-26       Impact factor: 5.150

5.  Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma.

Authors:  Hongyuan Chen; Ruizheng Miao; Junwei Fan; Zhongbo Han; Junyi Wu; Guoqiang Qiu; Huamei Tang; Zhihai Peng
Journal:  Clin Exp Metastasis       Date:  2013-02-03       Impact factor: 5.150

Review 6.  Guide for diagnosis and treatment of hepatocellular carcinoma.

Authors:  Magdy Hamed Attwa; Shahira Aly El-Etreby
Journal:  World J Hepatol       Date:  2015-06-28

7.  MicroRNA-147 suppresses proliferation, invasion and migration through the AKT/mTOR signaling pathway in breast cancer.

Authors:  Yulong Zhang; H E Zhang; Zhe Liu
Journal:  Oncol Lett       Date:  2015-10-29       Impact factor: 2.967

Review 8.  Modulation of immune responses following solid organ transplantation by microRNA.

Authors:  Nayan J Sarma; Venkataswarup Tiriveedhi; Sabarinathan Ramachandran; Jeffrey Crippin; William Chapman; T Mohanakumar
Journal:  Exp Mol Pathol       Date:  2012-10-01       Impact factor: 3.362

9.  MiR-19a is correlated with prognosis and apoptosis of laryngeal squamous cell carcinoma by regulating TIMP-2 expression.

Authors:  Tian-Yi Wu; Tian-Hong Zhang; Ling-Mei Qu; Jia-Peng Feng; Lin-Li Tian; Bing-Hui Zhang; Dan-Dan Li; Ya-Nan Sun; Ming Liu
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

10.  Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.

Authors:  Burcu Gurer Giray; Gurol Emekdas; Seda Tezcan; Mahmut Ulger; Mehmet Sami Serin; Orhan Sezgin; Engin Altintas; Eyup Naci Tiftik
Journal:  Mol Biol Rep       Date:  2014-03-05       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.